VIDEO: Eric J. Velazquez, MD talks PIONEER-HF Results for Acute Decompensated HF

Eric J. Velazquez, MD, Robert W. Berliner Professor of Cardiology and Chief of the Section of cardiovascular medicine in the department of internal medicine at Yale University School of Medicine, Chief of cardiovascular medicine at Yale New Haven Hospital and physician-in-chief of the Heart and Vascular Center for the Yale-New Haven Health System talks with DocWire News about the results of the PIONEER-HF trial presented at the  2018 American Heart Association Scientific Sessions.

According to Dr. Velazquez, patients with acute decompensated HF had greater reduction in N-terminal pro-B-type natriuretic peptide when assigned sacubitril/valsartan than treatment with enalapril.  Sacubitril/valsartan (Entresto, Novartis) was also superior to enalapril for a secondary serious composite clinical endpoint of death, HF rehospitalization, left ventricular assist device implantation or transplant listing at 8 weeks. The two treatments did not differ in the safety endpoints of worsening renal function, hyperkalemia, symptomatic hypotension and angioedema.

The study was presented on November 11, 2018 in Chicago.